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An overview of randomised controlled trials of adjuvant chemotherapy in
head and neck cancer
AJ Munro
Department ofRadiotherapy, St Bartholomew's Hospital, West Smithfield, London ECIA 7BE, UK.
Summary Meta-analysis of the published results from 54 randomised controlled trials of adjuvant
chemotherapy in head and neck cancer suggests that chemotherapy might increase absolute survival by 6.5%
(95% confidence interval 3.1-9.9%). The odds ratio in favour of chemotherapy is 1.37 (95% confidence
interval 1.24-1.5). Single-agent chemotherapy given synchronously with radiotherapy increased survival by
12.1% (95% confidence interval 5-19%). The benefit from neoadjuvant chemotherapy was less: a rate
difference of 3.7% (95% confidence interval 0.9-6.5%). The results suggest that the investigation of optimal
agents and scheduling for synchronous radiotherapy and chemotherapy might still be important in clinical
trials in head and neck cancer.
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Attitudes towards cytotoxic chemotherapy for squamous car-
cinomas of the head and neck range from enthusiasm
(Dimery and Hong, 1993) to disdain (Tannock and Brow-
man, 1986; Taylor, 1987). Response rates to chemotherapy
are high, but this responsiveness does not appear to translate
into durable benefit in terms of survival. Recent meta-
analyses of adjuvant chemotherapy for squamous cell car-
cinoma of the head and neck failed to show any benefit from
such treatment (Stell and Rawson, 1990; Stell, 1992). How-
ever, several randomised trials published subsequently have
been reported as showing benefit from adding chemotherapy
to standard therapy. In order better to define the possible
role for chemotherapy and to suggest possibly fruitful
avenues for exploration, a further meta-analysis of published
randomised clinical studies of adjuvant chemotherapy in
head and neck cancer has been performed.
The primary purpose of this overview was to discover
whether the addition of chemotherapy to definitive standard
therapy improved survival in patients with cancer of the head
and neck. Secondary objectives included an assessment of
whether the timing of chemotherapy, before, during or after
standard therapy, was important; a specific assessment of the
effectiveness of platinum/5-fluorouracil (5-FU) regimens; an
evaluation of single-agent chemotherapy given synchronously
with radiotherapy; an assessment of the effect of
chemotherapy upon locoregional control rates; an assessment
of the effect of chemotherapy upon the occurrence of distant
metastases.
Materials and methods
A structured search was conducted to identify randomised
clinical trials of chemotherapy in head and neck cancer. A
trial was suitable for inclusion if it fulfilled the following
criteria.
* published between January 1963 and August 1993;
* allocation of treatment was said to be randomised;
* there was a control arm in which patients did not receive
chemotherapy;
* Results were available for survival, disease-free survival or
local control.
Abstracts as well as published papers were acceptable. If
the same data had been published more than once, the most
recent data were used. Several complementary search pro-
cedures were used: MEDLINE search; a review of the
Physicians' Data Query (Silver Platter) clinical trials data-
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base; review of the relevant sections in the two available
volumes of Randomized Trials in Cancer: A Critical Review
by Sites (Cachin, 1978; Dodion et al., 1986); a systematic
review of every volume of the published proceedings of the
American Society of Clinical Oncologists from 1979 to
1993.
The data were abstracted from photocopies of the original
publications and entered onto a spreadsheet (Excel 4.0).
Trials were classified as follows:
* neoadjuvant, chemotherapy given before definitive
therapy;
* synchronous, chemotherapy given synchronously with
radiotherapy;
* post-definitive, chemotherapy given after definitive
therapy.
Some trials combined more than one of the above com-
ponents; such trials were classified according to the earliest
appearance of chemotherapy in the protocol. For example, a
trial involving two courses of chemotherapy then surgery,
then maintenance chemotherapy would simply be classified as
neoadjuvant.
The analysis was performed on published data: no attempt
was made to obtain data on individual patients. The times at
which survival was reported varied between studies. The
maximum survival interval available was used with an upper
limit of 5 years. Survival data, therefore, apply only to the
particular time point available for each trial. No allowance
has been made for the inevitable censoring within trials or
for differential censoring between trials. Wherever possible,
the raw numbers were used: in the absence of such data the
numbers were estimated from the published survival curves.
The values were obtained by applying a set square to the
survival curve at the specified time point, reading off the
percentage surviving, and thereby calculating, from the total
number randomised to that group, the absolute number of
survivors. The validity of the abstracted data was assessed by
repeated cross-checking and also, where possible, by com-
parison with the data presented in previous overviews (Stell
and Rawson, 1990; Stell, 1992). Of necessity, however, the
data used are crude and, at best, approximate.
The estimation of the number of events in the control and
experimental arms is, when there is no access to data on
individual patients, subject to a number of possible biases.
Two possible sources of bias are: differential censoring
between the two arms of the trial so that the denominator in
the experimental arm is proportionally lower than that in the
control arm, thereby exaggerating the benefit of the experi-
mental therapy; and systematic errors in extracting the data
from published reports so that the survival rate is con-
sistently overestimated in the experimental arm and con-
sistently underestimated in the control arm. Sensitivity000 -AJ Mni
analyss have been used to investigate the possible effects of
this type of bias upon the conclusions. Two approaches were
used. In the first approach the number of survivors in the
experimental group was decreased, and the number of sur-
vivors in the control group increased by a constant percent-
age for al trials. The second apprach was similar except
that, inead ofa fixed percntage correction being applied to
all trials, a different percetage correction was applied to
each trial. Tlhis correction varied aomly within spified
limits. The first approach gives an indication of the robust-
ness of any conclusions, while the second method perhap
reflects more accurately the true distnbution of any bias that
may arise. The calulations were as follows. If there were 60
estimated survivors in the group treated with chemohray
and 40 estimated survivors in the control group, and the bias
was 5%, the adjusted survival estimates were:
chemotherapy group 60- (0.05 x 60)=60-3=57
control group 40 + (0.05 x 40) =40 + 2=42
A further bias arises from the assumption, necessary for
the approach adopted in this paper, that the extracted data
are binomially distributed. The consequence is that the
stimated variances will be kss than the true varianc.
Statistical methods
This meta-nalysis has used two differnt statistical methods
for pooling data: the odds ratio method of Mantel-Haenszel
(Early Breast Cancer Triaists' Collaborative Group, 1990)
and the rate difference method by DerSimonian
and Laird (1986). The homognity and hetogeneity of the
pooled studies have been assessed both graphically and by
the Q-statistic (DerSimonian and Laird, 1986). Muliple com-
parisons have been made, in the subgroup analyses, and
therefore conservative P-vahles should be used for assng
signifcance.
The problem of publication bias has been addressed using
sensitivity analysis. The singe large trial method ascertains
the number of patients that would be required to overturn
the positive conclusion from a meta-analysis were there to be
a negtive trial that had not been identified for incusion in
the analysis. A similar approach is to estimate the number of
cnical trials of achievable size that would be required to
negate a positive conclusion. A further technique assesses the
possibility that a single positive trial might dominate the
analysis: positive trials are excluded sequentially, and in com-
bination, from the analysis and the effects upon the overall
conclusion are
The that a negative study is falseby negati has
been ased usimg the methol pulished by Detsky and
Sackett (1985). This method incorpores the advantage of
retrospectiv review.: the event rate in the control arm is
known, fewer a tions are required than in methods
designed to assess power and sample size prospectively.
Reks
Over 150 randomised trials in head and neck cancer were
identified. Of these, 54 fulfilled the criteria for inclusion in
this meta-analysis. These are summarisd in Table I. The
time at which the end point was assessed was unspecified in
9/54 studies and was less than 24 months in a further nine
stuie. The graphial assessment of homogeneity for the 51
comparisons of suvival data is shown in Figure 1. The trials
appear to be heterogeneous, and this is confirmed by the
Q-statistic of 111.1 which, on 50 degrees of freedom, corre-
sponds to a P-value of <10-': we can reject the null
hypothesis of homogeneity among trials. This degree of
inh oeneity is unsurpsing given the wide variations in
eigibility criteria and times chosen for the estiation of
survival.
The data for all 51 comparisons are presented in Table H.
The odds ratio, rate difference, x2 for difference in survival
*7V.
0.6
a Q5
a*u 0.5
2 04
= 03
g20
o 0.1
C) -'
0
l
*
m.
I I I
a * a a0* : * * U l
I I I I
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
Chemoteapy survval rat
Flgwe 1 Scatter plot of event rates for the comparisons of
survival data: ncoad, (U) neoadjuvant studie; post, (D)
chemotherapy given after definitive therapy-, synch (*)
othrapy given s r with radiotherapy.
F~e 2 The rate differen for the 51 c sons of survival
data Study numbers are the refernce numbers for each trial (see
Appendix). U, upper 95% limit by the l)Simonian
Laird nmehd; 0, lower 95% limit by the Der-
Siawnian Laird method.
between treatment and control arms and P-value calulated
from x2 are shown for each trial. Using P<0.05 as the
criterion for a positive result, only nine studies were positive
by both the rate difference and odds ratio methods; 39 were
negative by both methods and three were positive by the
odds ratio method but negative by the rate difference
method. For trials defined as non-sgnficant (P>0.05). the
probability that the result is a false negative has been shown
for a 25% relative increase in survival in the chemotherapy
arm. A relative increase in survival of25% corresponds to an
increase, in absolute terms, from 40% to 50% or from 16%
to 20%. Of the 42 negative comparisons, 14 had a >25%
probability of being false negative and five had a probability
of being false negative of >50%.
The 95% confidence limits of the rate differences are
shown in Figure 2. Trials lying above the zero axnis indicate
possible benefit from chemotherapy; trials lying below it
indcate a disadvantage from chemotherapy. Trials whose
confidence iEmits straddle the zero axis are, by this method,
non-sgnificant at the 0.05 level ofsign c. Figure 3 uses
a simila convention, but this time trials analysed by separate
categores: neoadjuvant studies, synchronous studie using
singie agents, and stui using platinum/5-FU combination
chemotherapy.
Table Ill shows the pooled estimates for odds ratio and
rate difference and their confidence limits. The table also
includes x2 for difference between the control and treatment
groups in terms of the end point spified, and Q-statistics
(for homogeneity). Data are shown for survival for the whole
group, and for the subgroups. Data on local control were
available from 43 comparisons and data on distant meta-
stases were available for 29 studies. These data are also
shown in Table Ill.
The meta-analysis shows that chemotherapy produces a
small, but clinicaly signifint improvement in survival:
6.9% with 95% confidence limits of 3.4% and 10.3%. The
difference is statsticaly highly significant, P<10-'°. This
conclusion is relatively insensitive to publication bias. Sensi-
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Table II Summary of survival data for the 51 comparisons
Rate RD RD Odds OR
duiff. low high ratio low
0.17 0.02 0.33 2.14 1.07
-0.31 -0.64 0.02 0.30 0.08
-0.09 -0.21 0.04 0.69 0.40
0.02 -0.22 0.26 1.08 0.40
0.28 0.04 0.53 4.62 1.20
-0.02 -0.18 0.14 0.88 0.34
0.02 -0.04 0.09 1.13 0.79
-0.05 -0.27 0.16 0.81 0.33
0.02 -0.17 0.20 1.07 0.50
0.03 -0.10 0.17 1.15 0.63
0.08 -0.01 0.17 1.39 0.95
0.09 -0.07 0.25 2.06 0.58
0.15 -0.07 0.37 1.80 0.73
0.05 -0.08 0.18 1.23 0.71
-0.03 -0.21 0.16 0.90 0.42
0.19 -0.08 0.47 2.56 0.57
0.09 -0.02 0.20 1.59 0.88
0.24 0.01 0.47 2.83 0.97
-0.01 -0.24 0.22 0.91 0.05
0.00 -0.25 0.25 1.00 0.37
0.02 -0.22 0.26 1.17 0.23
-0.04 -0.18 0.11 0.85 0.43
-0.02 -0.20 0.17 0.91 0.34
-0.12 -0.35 0.11 0.62 0.24
-0.02 -0.23 0.19 0.90 0.37
-0.04 -0.15 0.06 0.84 0.54
0.09 -0.15 0.33 1.43 0.53
0.02 -0.09 0.13 1.10 0.68
0.10 -0.01 0.21 1.53 0.96
-0.05 -0.31 0.21 0.76 0.17
0.00 -0.20 0.20 1.00 0.26
-0.08 -0.46 0.29 0.71 0.15
0.32 0.13 0.52 3.79 1.59
0.13 -0.04 0.30 2.89 0.66
0.13 -0.02 0.28 1.69 0.93
0.00 -0.12 0.11 0.98 0.50
0.36 0.05 0.67 4.63 1.10
0.19 0.02 0.37 2.38 1.05
0.13 -0.01 0.26 1.94 0.94
0.09 -0.02 0.20 1.41 0.91
0.04 -0.24 0.32 1.23 0.30
0.00 -0.13 0.14 1.02 0.59
0.19 0.05 0.33 2.94 1.32
0.10 -0.05 0.25 1.56 0.81
0.28 0.20 0.36 3.06 2.21
0.23 0.02 0.45 2.99 1.01
0.05 -0.08 0.17 1.21 0.71
0.06 -0.11 0.24 1.30 0.63
-0.11 -0.21 0.00 0.37 0.14
0.36 0.20 0.53 4.34 2.08
-0.17 -0.59 0.25 0.49 0.08
OR
high
4.27
1.16
1.17
2.86
17.85
2.25
1.63
2.00
2.27
2.12
2.02
7.36
4.45
2.12
1.94
11.44
2.88
8.26
15.62
2.73
5.91
1.67
2.44
1.60
2.19
1.30
3.87
1.78
2.41
3.27
3.88
3.31
9.03
12.72
3.05
1.90
19.52
5.37
4.01
2.20
4.97
1.76
6.53
2.99
4.24
8.92
2.06
2.67
0.98
9.05
2.95
Chi
sq
4.69
3.04
1.91
0.02
4.92
0.07
0.47
0.21
0.03
0.21
2.92
1.25
1.63
0.54
0.08
1.51
2.39
3.64
0.00
0.00
0.04
0.23
0.03
0.97
0.05
0.63
0.49
0.16
3.25
0.14
0.00
0.19
9.04
1.97
3.01
0.00
4.36
4.33
3.24
2.32
0.08
0.00
7.01
1.76
44.87
3.88
0.47
0.50
4.01
15.28
0.61
P for
sig. PFN
0.030
0.081 0.021
0.167 0.007
0.884 0.468
0.026
0.788 0.005
0.495 <.001
0.644 0.067
0.864 0.309
0.644 0.040
0.087 0.103
0.264 0.024
0.201 0.886
0.464 0.426
0.783 0.065
0.218 0.895
0.122 0.030
0.057 0.730
0.950 0.045
1.000 0.330
0.849 0.058
0.629 0.003
0.855 0.018
0.320 0.040
0.821 0.093
0.427 0.014
0.483 0.834
0.686 0.011
0.071 0.269
0.708 0.052
1.000 0.017
0.660 0.211
0.003
0.150 0.020
0.083 0.871
0.947 0.000
0.037
0.037
0.072 0.242
0.128 0.320
0.775 0.262
0.955 0.029
0.008
0.185 0.318
<.001
0.049
0.494 0.089
0.479 0.327
0.045
<.001
0.435 0.137
RD, rate difference; OR, Odds ratio; low, high, 95% confidence limits; Chi sq, x2 for significance; PFN, Probability that a
trial is false negative, given a 25% relative survival benefit for chemotherapy.
Table III Summary of pooled data
No. of No. of Pookd Low High Pooled Chi
Group studies patients RD (%) (%) (%) OR Low high squared P Q
All survival 52 7443 6.5 3.1 9.9 1.37 1.24 1.5 39.6 1E-09 117
All (locoregional control) 43 5389 7.9 1.9 13.9 1.44 1.28 1.63 37.2 lE-08 256
All (distant metastases) 29 4883 -1.9 -4.8 1.1 0.79 0.67 0.93 8.02 0.02 64
Platinum/SFU (survival) 8 1636 10.1 -4.7 25.0 1.56 0.81 2.99 4.91 0.025 11
Neoadjuvant (survival) 28 4141 3.7 0.9 6.5 1.2 1.04 1.35 6.4 0.011 20
Synchronous single agent 16 2506 12.1 5.0 19.0 1.77 1.51 2.1 54.7 IE-12 66
Chi squared is for significance. Q is for homogeneity and is analogous to a XI on (n-I) degrees of freedom, where n is
the number of studies. The null hypothesis is that the trials are homogeneous. Low and high refer to the lower and upper
bounds of the 95% confidence interval.
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49
51
52
14a
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7b
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10
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13
16
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53
55
56
42a
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142
32
229
65
46
100
638
78
108
187
446
75
75
218
107
36
237
59
23
60
39
158
85
68
82
332
63
292
303
40
56
34
84
58
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199
32
104
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116
20O0vwd how r Redcauw
AJ Munro
a a
0.
8
£ 0 C)
r-
I o
O
a
0%
Bias
b ;-T Ipv . XITII T T T I X
- 1 b
7a 42 53 S 11 i 64 5-10r-12-405-5 13 5 16 2 n
amp mo bo Mm S bba bo h h h I. mnewtOHUOMIJ pt o
0 0. Study drug
0
0
0
71
co bas co- bias rdm bin rwkm bias
Bias b
17 24 28 27 32 52 51 30 X 0
0
0
Study
Fuw 3 M, Upper 95% confidence limit by the DerSimonian
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Simonian Laird method. a, Rate differences for neoadjuvant
studies. b, Rate differences for studies of synchronous
chemotherapy and radiotherapy. c, Rate differences for adjuvant
chemotherapy with cisplatinum/5-fluorouracil.
Fugwe 4 Sensitivity analyses of bias in data presentation and
extraction. The method for correcting for possible bias is de-
scribed in the text. a, The rate difference method, with 95%
confidence intervals (DerSimonian and Laird). b, The odds ratio
method, with 95% confidence intervals (Peto).
with the data on survival. The data on distant metastases are,
in this respect, less consistent.
tivity analyses show that to overturn this positive conclusion
would require:
* an unreported trial containing 800 patients with 25%
survival in the chemotherapy group and 75% survival in
the control group.
or
* an unreported trial with 50% survival rate in each arm
and more than 20000 patients randomised.
Even adding 20 negative studies with survival rates of 33%
in each arm and 1200 patients randomised in each trial, the
overall x2 would still be 9.71 (P<0.005). No single study was
unduly influential. Eliminating significant studies in sequence
did not affect the conclusions. For example, even if the 11
most significant studies were eliminated completely, the
overall X2 was still 5.29 (P = 0.021).
The results from the sensitivity analyses dealing with pos-
sible bias in data publication and extraction are shown in
Figure 4. The robustness of the conclusion is sensitive to this
type of bias. A constant bias of 5% produces results similar
to a bias varying randomly for each trial between 0 and
10%; this again suggests that no one trial is unduly influ-
ential.
The subgroup analyses suggest that single-agent chemo-
therapy given with radiotherapy is particularly effective
- rate
difference 13.7% (95% CI 6.1-21.3%) - but neoadjuvant
chemotherapy is somewhat less effective - rate difference
3.9% (95% CI 1.1-6.7%). Platinum/5-FU regimens do not
appear to be outstandingly effective - rate difference 5.4%
(95% CI 0.1-10%). The data on local control are consistent
This overview of trials of adjuvant chemotherapy in head
and neck cancer suggests that chemotherapy might improve
survival and that this improvement is more apparent for
single-agent chemotherapy given synchronously with
radiotherapy. Since two previous meta-analyses (Stell and
Rawson, 1990; Stell, 1992) failed to show benefit from
chemotherapy, the discrepancies between these previous
analyses and the current results must be explained. Stell and
Rawson's first analysis (1990) included 23 trials, and the
updated analysis added five newer trials to give a total of 28
trials (Stell, 1992). The recent flurry of trial publication
means that there are now many more trials for analysis: 51
compansons for survival effect. The second overview was not
particularly robust: the z-value for overall survival was 1.24
(P>0.05). It would only be necessary to add a single trial
with a total of 380 patients randomised, with survival rates
of 47.3% in the chemotherapy arm and 34.2% in the control
arm, to convert this non-significant z-value to a significant
one.
Cumulative meta-analyses, and the current study could be
regarded as the third in a sequence for head and neck cancer,
can be useful for the prompt detection of therapeutic
advances. Experience from trials of treatment for myocardial
infarction showed that, although early overviews were
negative, the accumulation of evidence eventually favoured
active therapy (Antman et al., 1992; Lau et al., 1992).
The main disadvantage of the present analysis is that it is
based upon the published literature rather than upon data
from individual patients. This raises problems with the
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assessment of event rates (Stewart and Parmar, 1993). The
inability to use a constant time point for survival, for
example, introduces potentially serious bias since the survival
at arbitrary time points does not, and cannot, represent the
overall shape of the survival curve. The sensitivity analyses
clearly show that the overall conclusion of this overview is
sensitive to this type of bias. The only solution is to perform
a per-patient analysis, and such a study is currently under
way (MKB Parmar, 1994, personal communication). Unfor-
tunately, it will be at least 2 years until the results are
published; in the meantime literature-based analysis, with all
its imperfections, will have to suffice.
The present overview suggests that the largest gains, in
terms of survival, may be obtained by using chemotherapy
synchronously with radiotherapy. The demonstration that
gains from neoadjuvant therapy are relatively modest com-
pared with the benefits from synchronous therapy is pro-
vocative and, if true, would require an explanation consistent
with the basic biology of squamous carcinoma of the head
and neck. Squamous carcinomas of the head and neck have
high cell loss factors: 90% of cells produced by mitosis of
clonogenic cells may be lost through exfoliation and migra-
tion. Relatively modest killing of clonogens will, through the
effects of cell loss, produce rapid shrinkage of tumour. This
rapid regression, is, however, virtually an epiphenomenon -
albeit a gratifying one.
The ultimate outcome is dictated by those clonogenic cells
which are not lost and, in particular, their resistance to
therapy. Because of cell loss, a clinically apparent tumour is
genetically old, a 2 cm squamous cell carcinoma of the head
and neck is perhaps 600-1000 generations old. In the
absence of cell loss it would take only 30-40 generations to
reach this size. The chance of a mutation emerging that
confers drug resistance increases with each generation. There
is a high probability that, at diagnosis, even small tumours of
the head and neck will contain clonogenic cells which are, de
novo, resistant to cytotoxic drugs. Cell loss can therefore
explain both the initial responsiveness and the ultimate resist-
ance to chemotherapy of these tumours.
Accelerated repopulation of clonogenic cells in tumours
may compromise the effectiveness of radiotherapy for head
and neck cancers (Withers et al., 1988). Neoadjuvant chemo-
therapy, by providing the stimulus for such repopulation
several weeks before the start of radiotherapy, might exacer-
bate this problem. With synchronous chemotherapy, the
problem of such treatment-induced perturbations does not
apply.
The data on the effects of chemotherapy upon distant
metastasis are conflicting. This partly reflects the fact that
distant metastases are an uncommon cause of treatment
failure in head and neck cancer. The majority of patients
who die do so from local regional failure. The inability of
chemotherapy to prevent distant metastasis may therefore be
more apparent than real.
An overview has two main purposes: firstly to suggest
what, on the basis of data from clinical trials, might be
defined as reasonable current practice; secondly, to provide a
stimulus to further studies. Primary treatment with chemo-
therapy may provide useful relief of symptoms in patients
treated palliatively, but there is little justification for the
routine use of neoadjuvant chemotherapy in head and neck
cancer. The claim, from the Veterans Administration study
(The Department of Veterans Affairs Laryngeal Cancer
Study Group, 1991), that neoadjuvant chemotherapy offers
the possibility of avoiding mutilating surgery in head and
neck cancer is controversial since that study, by virtue of its
design, was unable to provide any evidence that chemo-
therapy plus radiotherapy was any better than radiotherapy
alone.
The data presented here suggest that we might put less
effort into neoadjuvant studies and return to a more detailed
investigation of the effectiveness of single-agent chemo-
therapy given synchronously with radiotherapy. Such treat-
ment is simple and inexpensive. The survival benefit may be
genuine: the next questions are what are the costs of such
benefit in terms of excess morbidity and which is the best
drug to use? Future trials will need to collect adequate data,
both objective and subjective, on the toxicity of treatment.
Radiation dose may also be important. It is essential that
trials of synchronous chemotherapy report the radiation
doses actually given, not simply those that were intended. If
synchronous chemotherapy increases acute morbidity and
necessitates the attentuation or curtailment of radiation
therapy, then there may be little overall gain. Trials designed
to answer these important questions need not be complex,
nor should their entry criteria be too restrictive. Large simple
studies are now required (Peto and Easton, 1989) to define
more precisely the contribution of synchronous chemo-
therapy to the radiotherapeutic management of head and
neck cancer.
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